Ovarian Cancer Drugs Market is expected to reach US$ 3.8 billion by 2030

Epithelial Ovarian Cancer Under Type Segment to Bolster Ovarian Cancer Drugs Market Size During 2022–2030

According to our latest study on "Ovarian Cancer Drugs Market Forecast to 2030 – Global Analysis – Type, Drug Class, and Distribution Channel," the market is expected to reach US$ 3.8 billion by 2030 from US$ 2.1 billion in 2022. The market report emphasizes the key factors driving the market and showcases the developments of prominent players. The rising incidence of ovarian cancer is a crucial factor propelling the ovarian cancer drugs market growth. However, product recalls due to adverse effects among patients impede the market growth.  

Regional Overview

Based on geography, the ovarian cancer drugs market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America; North America held the largest market share in 2022. The US dominates the market in North America. In addition to the rising incidence of ovarian cancer, fast drug approvals for treatments and the prominent presence of several contract clinical research organizations (CROs) favor ovarian cancer drugs market growth in the US. According to a report by the US Department of Health and Human Services, ~235,511 women were living with ovarian cancer in the US in 2020. Additionally, the American Cancer Society estimates that ~19,680 women in the US would be newly diagnosed with ovarian cancer in 2024, while nearly 12,740 patients are likely to die from the disease. In April 2020, the FDA announced approval for Niraparib (Zejula) manufactured by GSK for the treatment of epithelial ovarian cancer patients who completely or partially respond to the first-line platinum-based chemotherapy.   

Market Opportunity

Rising Research & Development (R&D) Activities to Accelerate Market Growth in Coming Years

Idetrexed, a drug discovered by created by a scientist team at the Institute of Cancer Research (ICR) to treat ovarian cancer, is on the verge of entering into a Phase 2 clinical trial. The drug has already produced promising outcomes in the Phase 1 clinical trial led by the researchers at the ICR. Phase 2 will further test "idetrexed" effectiveness and safety in a larger group of ovarian cancer patients.

The City of Hope (a private, nonprofit clinical research center and hospital), in its 2024 report, revealed that researchers developed CAR-T cell therapy for patients with advanced ovarian cancer. The therapy is currently in Phase 1 trial at the City of Hope Research Institute for patients suffering from epithelial ovarian cancer, who have already received platinum-based chemotherapy. This CAR-T cell therapy targets TAG72, a receptor found on the surface of ovarian cancer cells, and with this action, the candidate was found to eradicate cancer cells in mouse models. The TAG72 is also found on other cancer cells, including pancreatic, colorectal, breast, and brain tumors. Therefore, depending on the outcomes of the Phase 1 clinical trial for CAR-T cell therapy targeting TAG72, researchers at the City of Hope are likely to plan to investigate its effect on ovarian cancer cells.  Apart from market opportunity, the report covers the innovation in ovarian cancer drugs market trends and their foreseeable impact during the forecast period

Ovarian Cancer Drugs Market, by Type:

Based on type, the ovarian cancer drugs market analysis is carried out by considering the following subsegments: epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment held the largest ovarian cancer drugs market share in 2022; the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period.

Ovarian Cancer Drugs Market, by Drug Class:

By drug class, the ovarian cancer drugs market is segmented into PARP inhibitors, anti-angiogenesis inhibitors, and others. The PARP inhibitors segment held the largest ovarian cancer drugs market share in 2022. It is anticipated to register the highest CAGR of 8.2% during the forecast period.

Ovarian Cancer Drugs Market, by Distribution Channel:

By distribution channel, the ovarian cancer drugs market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022, and the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period.

Industry Developments and Future Opportunities:

In September 2022, AstraZeneca and Merck received approval for Lynparza (olaparib) in China for the maintenance treatment of adult patients suffering from advanced epithelial cancer. The newly approved candidate is the first-line platinum-based chemotherapy administered in combination with bevacizumab.

In November 2022, F. Hoffmann-La-Roche announced US Food and Drug Administration (USFDA) approval for "VENTANA FOLR1 (FOLR1-2.1) RxDx Assay". The newly launched product is the first immunohistochemistry (IHC) companion diagnostics test to aid in identifying epithelial ovarian cancer (EOC) patients. Folate receptor 1 protein (FOLR1), also known as folate receptor alpha (FRɑ), and expressed at some level in approx. 90% of ovarian carcinomas that serves as a predictive biomarker for FOLR1-targeted therapy for EOC patients and is the new test that informs clinicians about the likelihood of potential benefit from FOLR1 therapy advancing Roche's commitment to personalized healthcare through innovative solutions that helps fit the treatment for the individual.

Ovarian Cancer Drugs Market, by Geography:

The geographic scope of the ovarian cancer drugs market report encompasses North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). Developments and launch of new drugs by several market players, along with approvals by regulatory authorities, help in the market expansion.

Apart from factors driving the market, the ovarian cancer drugs market report emphasizes prominent players' developments. Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are among the prominent players operating in the market.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com